Skip to main content
. 2021 Jul 23;11(12):3008–3027. doi: 10.1158/2159-8290.CD-20-1631

Figure 1.

Figure 1. Patient accrual and demographic data. A, Consort diagram depicting patient accrual into G4K. *Three patients were removed from the study when pathology revealed that 1 patient had no cancer, another patient died before a germline sample could be collected, and another patient declined return of germline results and there was insufficient tumor for sequencing. B, Age distribution of patients. C, Number of patients with newly diagnosed or relapsed or refractory tumors, or no tumor available for sequencing, broken down by major tumor type. D, The distribution of cancer types represented in the G4K cohort (top) compared to the distribution of pediatric cancers in the NCI SEER program (bottom). ACT, adrenocortical tumor; STS, soft-tissue sarcoma. E, Eighteen rare tumor types found in the G4K cohort. Rare tumor types were defined as those present at less than 2 per million children annually in the United States.

Patient accrual and demographic data. A, Consort diagram depicting patient accrual into G4K. *Three patients were removed from the study when pathology revealed that 1 patient had no cancer, another patient died before a germline sample could be collected, and another patient declined return of germline results and there was insufficient tumor for sequencing. B, Age distribution of patients. C, Number of patients with newly diagnosed or relapsed or refractory tumors, or no tumor available for sequencing, broken down by major tumor type. D, The distribution of cancer types represented in the G4K cohort (top) compared to the distribution of pediatric cancers in the NCI SEER program (bottom). ACT, adrenocortical tumor; STS, soft-tissue sarcoma. E, Eighteen rare tumor types found in the G4K cohort. Rare tumor types were defined as those present at less than 2 per million children annually in the United States.